131 related articles for article (PubMed ID: 26752869)
1. Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection.
Costiniuk CT; Gosnell BI; Manzini TC; Du Plessis CN; Moosa MY
J Glob Infect Dis; 2015; 7(4):151-6. PubMed ID: 26752869
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK.
Abbara A; Chitty S; Roe JK; Ghani R; Collin SM; Ritchie A; Kon OM; Dzvova J; Davidson H; Edwards TE; Hateley C; Routledge M; Buckley J; Davidson RN; John L
BMC Infect Dis; 2017 Mar; 17(1):231. PubMed ID: 28340562
[TBL] [Abstract][Full Text] [Related]
3. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests.
Patterson B; Abbara A; Collin S; Henderson M; Shehata M; Gorgui-Naguib H; Lynn W; Kon OM; John L
J Infect; 2021 Feb; 82(2):240-244. PubMed ID: 33271167
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury.
Naidoo S; Evans D; Jong E; Mellet K; Berhanu R
S Afr Med J; 2015 Apr; 105(5):393-6. PubMed ID: 26242667
[TBL] [Abstract][Full Text] [Related]
5. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system.
Raj Mani SS; Iyyadurai R; Mishra AK; Manjunath K; Prasad J; Lakshmanan J; Yadav B; Reginald A; Jasmine S; Hansdak SG; Zachariah A
Int J Mycobacteriol; 2021; 10(2):116-121. PubMed ID: 34558461
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis.
Sharma P; Tyagi P; Singla V; Bansal N; Kumar A; Arora A
J Clin Exp Hepatol; 2015 Mar; 5(1):8-13. PubMed ID: 25941429
[TBL] [Abstract][Full Text] [Related]
7. Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort.
Moosa MS; Maartens G; Gunter H; Allie S; Chughlay MF; Setshedi M; Wasserman S; Stead DF; Cohen K
South Afr J HIV Med; 2022; 23(1):1376. PubMed ID: 35923608
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.
Saha A; Shanthi F X M; Winston A B; Das S; Kumar A; Michael JS; Balamugesh T
J Prim Care Community Health; 2016 Jul; 7(3):171-4. PubMed ID: 27056794
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea.
Lim J; Kim JS; Kim HW; Kim YH; Jung SS; Kim JW; Oh JY; Lee H; Kim SK; Kim SH; Lyu J; Ko Y; Kwon SJ; Jeong YJ; Kim DJ; Koo HK; Jegal Y; Kyung SY; An TJ; Min J
Open Forum Infect Dis; 2023 Aug; 10(8):ofad422. PubMed ID: 37654787
[TBL] [Abstract][Full Text] [Related]
10. Antitubercular therapy induced liver function tests abnormalities in human immunodeficiency virus infected individuals.
Puri P; Kaur N; Pathania S; Kumar S; Sharma PK; Sashindran VK
Med J Armed Forces India; 2017 Jan; 73(1):12-17. PubMed ID: 28123239
[TBL] [Abstract][Full Text] [Related]
11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
12. Novel risk factors and early detection of anti tubercular treatment induced liver injury-Looking beyond American Thoracic Society Guidelines.
Latief M; Dar WR; Sofi N; Dar IA; Kasana B; Hussain M; Arshad F; Shah BA; Koul PA
Indian J Tuberc; 2017 Jan; 64(1):26-32. PubMed ID: 28166913
[TBL] [Abstract][Full Text] [Related]
13. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa.
Jeena PM; Pillay P; Pillay T; Coovadia HM
Int J Tuberc Lung Dis; 2002 Aug; 6(8):672-8. PubMed ID: 12150478
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.
Kim WS; Lee SS; Lee CM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ; Hong JW; You HS; Cho HC
BMC Infect Dis; 2016 Feb; 16():50. PubMed ID: 26833347
[TBL] [Abstract][Full Text] [Related]
15. Malnutrition as an important risk factor for drug-induced liver injury in patients on anti-tubercular therapy: an experience from a tertiary care center in South India.
Ali N; Gupta N; Saravu K
Drug Discov Ther; 2020; 14(3):135-138. PubMed ID: 32669522
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Prophylactic Use of Hepatoprotectants for Tuberculosis Drug-Induced Liver Injury: A Population-Based Cohort Analysis Involving 6,743 Chinese Patients.
Chen Q; Hu A; Ma A; Jiang F; Xiao Y; Chen Y; Huang R; Yang T; Zhou J
Front Pharmacol; 2022; 13():813682. PubMed ID: 35517815
[No Abstract] [Full Text] [Related]
17. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment.
Chen L; Bao D; Gu L; Gu Y; Zhou L; Gao Z; Huang Y
BMC Infect Dis; 2018 Jul; 18(1):295. PubMed ID: 29970037
[TBL] [Abstract][Full Text] [Related]
18. Antituberculous drug-induced liver injury: current perspective.
Devarbhavi H
Trop Gastroenterol; 2011; 32(3):167-74. PubMed ID: 22332331
[TBL] [Abstract][Full Text] [Related]
19. An official ATS statement: hepatotoxicity of antituberculosis therapy.
Saukkonen JJ; Cohn DL; Jasmer RM; Schenker S; Jereb JA; Nolan CM; Peloquin CA; Gordin FM; Nunes D; Strader DB; Bernardo J; Venkataramanan R; Sterling TR;
Am J Respir Crit Care Med; 2006 Oct; 174(8):935-52. PubMed ID: 17021358
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
